Biogen CEOMichel Vounatsos to Resign

The move comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.

The move comes as the company attempts to chart a new course following Medicare’s refusal to cover its new Alzheimer’s drug Aduhelm.

Source: Read More

PAID

Leave a Comment